Molina Healthcare enters its July 22 earnings call in an unusual position: the stock has run 22% in a month, short sellers have rebuilt positions, and virtually every analyst on the Street still has a neutral or bearish rating — with price targets that the market has already blown past.
The most striking tension this week is the gap between where analysts think MOH is worth and where it is trading. The consensus mean target is $190.88, against a current price of $232.90 — a discount of nearly 18% to the tape. Recent moves show the Street scrambling to catch up. JP Morgan raised its target from $169 to $191 in early June; Morgan Stanley lifted from $146 to $167; Barclays, which carries an Underweight, bumped its target to $199. None of it has been enough. RBC initiated coverage on June 23 at Sector Perform with a $216 target — still below the current price. The analyst recommendation divergence score ranks in the 95th percentile across ORTEX's universe, meaning the gap between where MOH trades and what the Street recommends is historically extreme. That divergence is itself a data point: bulls are driving this name while the institutional analyst community watches from the sidelines.
Short interest has rebuilt quietly as the stock climbed. At 5.9% of the free float — up roughly 8% over the past month — there is a genuine short base here, not a trivial one. The incremental rebuilding through June coincided almost exactly with the price surge, suggesting sellers leaning against the momentum rather than a fundamental conviction short. Cost to borrow remains negligible at 0.45%, up 35% on the week but still in the low single digits — not a number that implies any conviction about a squeeze. Availability is loose at over 1,000%, meaning there is no shortage of stock to borrow. The borrow market is not where the tension lives.
Options positioning is mildly defensive but not alarmed. The put/call ratio is running at 1.09, slightly above its 20-day average of 1.06, with a z-score of just 0.5 — well within the normal range. For comparison, the 52-week high PCR was 1.60, so current hedging looks measured rather than fearful. Peers are broadly supportive: ELV rose nearly 8% on the week, CNC added 2.4%, and UNH gained 2%. MOH's 1.8% weekly gain actually trails its closest peers, which is notable given the bigger month it has had.
The earnings history adds another layer of complexity. Two prints back — April 22-23 — MOH delivered back-to-back sessions that moved the stock 15% and 16% higher on the day, with five-day follow-throughs of 30% and 27% respectively. The May 8 print reversed that, falling 3.5% on the day. The pattern suggests the stock responds sharply to surprises in either direction. EPS momentum factors rank in the 93rd percentile on a 30-day basis and 84th on 90 days — the forward revision trend is strong, which partially explains why the stock is trading well above consensus targets. But the EPS surprise rank sits at just the 15th percentile, meaning the company has not consistently beaten estimates in recent periods. That combination — rising estimates, low recent beat rate — makes the July 22 print harder to call.
Institutional ownership shows BlackRock increased its stake by 2.5 million shares as of June 30, making it the largest holder at 12.2% of shares. AQR nearly quadrupled its position. Both additions appear to have occurred into a rising tape, not as value buys at the lows.
The July 22 earnings call is the next hard catalyst. What to watch is whether the margin story — specifically Medicaid reimbursement rates and the four-state concentration risk that bears keep flagging — shows any improvement, and whether management's guidance can give the analyst community enough confidence to finally close the gap between their targets and the price.
See the live data behind this article on ORTEX.
Open MOH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
